PERSPECTIVE: Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp)
Bekaii-Saab, T. S., Van Cutsem, E., Cubillo, A., Petorin-Lesens, C., Rodriguez-Salas, N., Raghav, K. P. S., . . . Tabernero, … Read More
